RGMP.US Regnum Corp

Communication Services Biotechnology USA Stocks
0.0001 USD
Close of Oct 20, 2025
0.0001 0.0001
Market cap
USD 2.30K
P/E
-
P/B
7,857.73x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is RGMP.US undervalued?

Graham number

The Graham number of Regnum Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regnum Corp fundamental analysis

No fundamental analysis for Regnum Corp yet.

Regnum Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regnum Corp

Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.

Full company profile